

Supplementary table 1: Treatment scheme modified according to decision by local Hospital Commission

	First phase (March 12 <sup>th</sup> to March 20 <sup>th</sup> )	Second Phase (March 21 <sup>th</sup> to April 10 <sup>th</sup> )	Dosages/duration
Hydroxychloroquine	Yes	Yes	400mg/12h on day 1 followed by 200mg/12h/ 10-14 days
Lopinavir/ritonavir	Yes	Yes	400 mg/100 mg twice a day 10-14 days
β-Interferon	Yes	No	250 µg sc/48 h 10 days
Azythromycin	No	Yes	500 mg on day 1, followed by 250 mg per day for the next 4 days/ 5days
Corticosteroids *	No	Yes	1 mg/kg/day intravenous 5 days
Tocilizumab **	Yes	Yes	< 75 Kg: 400 mg iv >75 kg: 600 mg iv 1 day

sc: subcutaneous, iv: intravenous

\*Corticosteroids were indicated in case of interstitial bilateral pneumonia with severe respiratory failure

\*\*Tocilizumab was indicated with these criteria: Interstitial pneumonia with severe respiratory failure (score = 2)/ Rapid respiratory worsening requiring non-invasive or invasive ventilation (COVID respiratory severity scale  $\geq 3$ )/ Presence of extrapulmonary organic failure (mainly Shock or SOFA score  $\geq 3$ )/ Presence of Critical Systemic Inflammatory Response criteria: high levels of IL-6 ( $> 40$  pg / ml) or, alternatively, high levels of dimer-D ( $> 1500$ ) or D-dimer in progressive increase/ Patients likely to be admitted to the ICU according to the criteria in force in each hospital

Table S2: Risk factors associated with in-hospital death

Variables analyzed	Univariable HR	p value	Adjusted HR	P value
<b>Demographic and dialysis characteristics</b>				
Age(years)	1.050(0.984-1.121)	0.140	1.070(0.990-1.156)	0.086
Hemodialysis time (months)	1.007(1.000-1.003)	0.039	1.008(1.001-1.015)	0.019
Charlson comorbidity Index	0.772(0.533-1.117)	0.170		
O <sub>2</sub> baseline saturation(%)	0.901(0.815-0.996)	0.041		
<b>Laboratory findings(7 days)</b>				
<b>Model 1</b>				
Age(years)	1.050(0.984-1.121)	0.140	1.058(0.956-1.171)	0.272
Lymphocyte count (x10 <sup>9</sup> )	0.996(0.992-1.000)	0.034	0.996(0.992-1.000)	0.056
<b>Model 2</b>				
Age(years)	1.050(0.984-1.121)	0.140	1.092(0.984-1.212)	0.097
LDH(U/l)	1.004(1.001-1.008)	0.023	1.006(1.001-1.011)	0.016
<b>Treatment scheme</b>				
<b>Model 3</b>				
Age (years)	1.050(0.984-1.121)	0.140	1.116(1.008-1.236)	0.035
Azithromycin	0.130(0.016-1.036)	0.054	0.057(0.005-0.697)	0.025
Lopinavir/ritonavir	0.328(0.041-2.622)	0.293	0.969(0.107-0.874)	0.978
<b>Model 4</b>				
Age (years)	1.050(0.984-1.121)	0.140	1.064(0.996-1.138)	0.067
Corticosteroids(yes)	0.181(0.039-0.843)	0.029	0.154(0.033-0.724)	0.018

Table S3. Baseline characteristics, clinical and radiological features comparing patients who received either Azithromycin or corticosteroids with those who did not receive these treatments.

	<b>Azithromycin (no) (n=23)</b>	<b>Azithromycin (yes) (n=13)</b>	<b>p</b>
Age, years	70±12	73±13	0.370
Male	14(64%)	9(69%)	0.448
Body mass Index	26.8± 4.9	26,2 ±3.2	0.724
<b>Comorbidities</b>			
Hypertension	22(96%)	13(100%)	1.000
Diabetes	14(61%)	9(69%)	0.727
Coronary heart disease	5(22%)	3(23%)	1.000
Dyslipidemia	15(65%)	9/69%	1.000
Chronic obstructive lung disease	5(22%)	2(15%)	1.000
Atrial fibrillation	6(26%)	5(38%)	0.475
Charlson index	5,39 ± 1,92	5,85 ± 1,51	0.469
<b>Symptoms</b>			
Fever	14 (61%)	10(77%)	0.467
Cough	11(48%)	5(38%)	0.731
Fatigue	7(30%)	2(15%)	0.438
Diarrhoea, nausea or vomiting	3(13%)	3(23%)	0.645
Time from illness onset to hospital admission (days)	3.04(0-15)	2.46(0-7)	0.584
Basal Oxygen saturation	93.2±4.9	94.4±3.1	0.406
<b>Admission Chest X-Ray</b>			
Bilateral peripheral ground-glass opacity	17(65%)	7(54%)	0.551
Unilateral opacity	4(17%)	2(15%)	
Normal X-ray	4(17%)	3(23%)	
<b>Mortality (yes)</b>	10(43%)	1(8%)	0.031

	<b>Corticosteroids(no) (n=19)</b>	<b>Corticosteroids (yes) (n=17)</b>	<b>p</b>
Age, years	70.1 ± 13.3	71.9 ± 11.4	0.662
Male	13 (68%)	10 (59%)	0.730
Body mass Index	25.9 ± 3.05	27.3 ± 5.48	0.427
<b><u>Comorbidities</u></b>			
Hypertension	18 (95%)	17 (100%)	1.000
Diabetes	11 (58%)	12 (71%)	0.502
Coronary heart disease	4 (21%)	4 (23.5%)	1.000
Dyslipidemia	12 (63%)	12 (71%)	0.732
Chronic obstructive lung disease	3 (16%)	4 (23.5%)	0.684
Atrial fibrillation	7 (37%)	4 (23.5%)	0.481
Charlson index	5.21 ± 1.9	5.94 ± 1.6	0.224
<b><u>Symptoms</u></b>			
Fever	12 (63%)	12 (71%)	0.732
Cough	8 (42%)	8 (47%)	1.000
Fatigue	6 (32%)	3 (18%)	0.451
Diarrhoea, nausea or vomiting	1 (5%)	4 (23.5%)	0.391
Time from illness onset to hospital admission (days)	3.00 (0-10)	2.45 (0-15)	0.579
Basal Oxygen saturation	93.5 ± 5.3	93.4 ± 3.2	0.874
<b><u>Admission Chest X-Ray</u></b>			
Bilateral peripheral ground-glass opacity	10 (53%)	12 (71%)	0.273
Unilateral opacity	5 (26%)	2 (12%)	
Normal X-ray	4 (21%)	3 (17%)	
<b><u>Mortality (yes)</u></b>	9 (48%)	2 (11%)	0.031